NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00186966,Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT00186966,,COMPLETED,"This is an international multicenter open label randomized phase III trial in children with relapsed and refractory acute myeloid leukemia (AML) such a disease. The main purpose of this study is to determine the efficacy and toxicity of liposomal daunorubicin when added to fludarabine, ara-C and G-CSF(FLAG) in children with relapsed and refractory AML.",NO,Acute Myeloid Leukemia,"DRUG: Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|DRUG: Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|PROCEDURE: Hematopoietic stem cell transplant|RADIATION: Total body irradiation","Response Rate, 8-9 years","Toxicity between two arms, 8-9 years",,Dutch Childhood Oncology Group,International BFM Study Group|St. Jude Children's Research Hospital,ALL,"CHILD, ADULT",PHASE3,394,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,TRIAL|TRIAL Relapsed AML 2001/01,2002-03,2009-04,2010-09,2005-09-16,,2011-04-06,"St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States",
